© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 7, 482-490,
April 3, 2002
© 2002 Oxford University Press
ARTICLE |
Tazarotene-Induced Gene 1 (TIG1) Expression in Prostate Carcinomas and Its Relationship to Tumorigenicity
Affiliations of authors: C. Jing, M. A. El-Ghany, C. Beesley, C. S. Foster, P. Smith, Y. Ke (Molecular Pathology Laboratory, Department of Pathology, Faculty of Medicine) and P. S. Rudland (School of Biological Sciences) University of Liverpool, U.K.
Correspondence to: Dr. Youqiang Ke, Molecular Pathology Laboratory, Department of Pathology, Faculty of Medicine, University of Liverpool, P.O. Box 147, Liverpool, L69 3BX, U.K. (e-mail: yqk{at}Liverpool.ac.uk).
Background: Prostate cancer is the most common noncutaneous male cancer and one of the least understood malignant diseases. Identifying key genetic factors involved in the metastasis of prostate cancer cells is critical. In this study, we used selective subtractive differential gene display to identify a gene whose decreased expression may contribute to the growth and expansion of prostate cancer. Methods: We used 192 primer pair combinations and polymerase chain reaction technology to identify genes expressed in the benign prostate cell line PNT-2 but not in the malignant prostate cancer cell lines LNCaP, Du-145, PC-3, or PC-3M. The tazarotene-induced gene 1 (TIG1) was chosen for further study. TIG1 expression in normal tissues and cell lines was analyzed by northern blot and in normal and tumor prostate tissue sections by in situ hybridization. The in vitro invasiveness (migration through extracellular matrix) and in vivo tumorigenicity (growth in nude mice) were assessed for the highly malignant PC-3M cell line transfected with TIG1 or control cDNA. All statistical tests were two-sided. Results: TIG1 mRNA was expressed in a variety of normal tissues other than prostate tissue. TIG1 mRNA was detected in all 10 normal human prostate tissues and all 51 benign prostatic hyperplastic tissues analyzed but in only four of 51 malignant prostate tissues analyzed. Compared with vector-transfected cells, transfection of PC-3M cells with TIG1 decreased in vitro invasiveness from 14.7% to 3.7%, (mean difference = 11%; 95% confidence interval [CI] = 9.2% to 12.8%, P<.001) and decreased in vivo tumorigenicity from an average tumor weight of 1.31 g to 0.55 g, (mean difference = 0.76 g; 95% CI = 0.43 to 1.09 g, P<.001). Conclusion: TIG1 may be a tumor suppressor gene whose diminished expression is involved in the malignant progression of prostate cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Nakamura, T. Kuwai, Y. Kitadai, T. Sasaki, D. Fan, K. R. Coombes, S.-J. Kim, and I. J. Fidler Zonal Heterogeneity for Gene Expression in Human Pancreatic Carcinoma Cancer Res., August 15, 2007; 67(16): 7597 - 7604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bee, Y. Ke, S. Forootan, K. Lin, C. Beesley, S. E. Forrest, and C. S. Foster Ribosomal protein l19 is a prognostic marker for human prostate cancer. Clin. Cancer Res., April 1, 2006; 12(7): 2061 - 2065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Zorn, T. Bonome, L. Gangi, G. V.R. Chandramouli, C. S. Awtrey, G. J. Gardner, J. C. Barrett, J. Boyd, and M. J. Birrer Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer Clin. Cancer Res., September 15, 2005; 11(18): 6422 - 6430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Konishi, M. Nakamura, E. Ishida, K. Shimada, E. Mitsui, R. Yoshikawa, H. Yamamoto, and K. Tsujikawa High Expression of a New Marker PCA-1 in Human Prostate Carcinoma Clin. Cancer Res., July 15, 2005; 11(14): 5090 - 5097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Takai, N. Kawamata, C. S. Walsh, S. Gery, J. C. Desmond, S. Whittaker, J. W. Said, L. M. Popoviciu, P. A. Jones, I. Miyakawa, et al. Discovery of Epigenetically Masked Tumor Suppressor Genes in Endometrial Cancer Mol. Cancer Res., May 1, 2005; 3(5): 261 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-L. So, K. Lee, J. Hebert, P. Walker, Y. Lu, J. Hwang, L. Kopelovich, M. Athar, D. Bickers, M. Aszterbaum, et al. Topical Tazarotene Chemoprevention Reduces Basal Cell Carcinoma Number and Size in Ptch1+/- Mice Exposed to Ultraviolet or Ionizing Radiation Cancer Res., July 1, 2004; 64(13): 4385 - 4389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Wood, L. Tchack, G. Angelo, R. E. Pratt, and L. A. Sonna DNA microarray analysis of vitamin D-induced gene expression in a human colon carcinoma cell line Physiol Genomics, April 13, 2004; 17(2): 122 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Youssef, X.-q. Chen, E. Higuchi, Y. Kondo, G. Garcia-Manero, R. Lotan, and J.-P. J. Issa Hypermethylation and Silencing of the Putative Tumor Suppressor Tazarotene-Induced Gene 1 in Human Cancers Cancer Res., April 1, 2004; 64(7): 2411 - 2417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.A. Schulz, M. Burchardt, and M.V. Cronauer Molecular biology of prostate cancer Mol. Hum. Reprod., August 1, 2003; 9(8): 437 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Tokumaru, D.-I. Sun, S. Nomoto, K. Yamashita, and D. Sidransky Re: Is TIG1 a New Tumor Suppressor in Prostate Cancer? J Natl Cancer Inst, June 18, 2003; 95(12): 919 - 920. [Full Text] [PDF]
|
|
|
|
|
|
R. Lotan Is TIG1 a New Tumor Suppressor in Prostate Cancer? J Natl Cancer Inst, April 3, 2002; 94(7): 469 - 470. [Full Text] [PDF]
|
|